|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUDT2 |
Gene summary for NUDT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUDT2 | Gene ID | 318 |
| Gene name | nudix hydrolase 2 | |
| Gene Alias | APAH1 | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P50583 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 318 | NUDT2 | LZE3D | Human | Esophagus | HGIN | 4.85e-03 | 4.08e-01 | 0.0668 |
| 318 | NUDT2 | LZE4T | Human | Esophagus | ESCC | 1.23e-06 | 6.46e-02 | 0.0811 |
| 318 | NUDT2 | LZE5T | Human | Esophagus | ESCC | 3.17e-02 | 1.03e-01 | 0.0514 |
| 318 | NUDT2 | LZE7T | Human | Esophagus | ESCC | 1.15e-06 | 3.58e-01 | 0.0667 |
| 318 | NUDT2 | LZE8T | Human | Esophagus | ESCC | 1.67e-03 | -2.15e-02 | 0.067 |
| 318 | NUDT2 | LZE22T | Human | Esophagus | ESCC | 2.29e-04 | 2.12e-01 | 0.068 |
| 318 | NUDT2 | LZE24T | Human | Esophagus | ESCC | 3.74e-13 | 3.46e-01 | 0.0596 |
| 318 | NUDT2 | LZE6T | Human | Esophagus | ESCC | 6.23e-04 | 1.04e-01 | 0.0845 |
| 318 | NUDT2 | P1T-E | Human | Esophagus | ESCC | 5.05e-04 | 1.71e-01 | 0.0875 |
| 318 | NUDT2 | P2T-E | Human | Esophagus | ESCC | 6.12e-23 | 3.88e-01 | 0.1177 |
| 318 | NUDT2 | P4T-E | Human | Esophagus | ESCC | 5.78e-10 | 2.55e-01 | 0.1323 |
| 318 | NUDT2 | P5T-E | Human | Esophagus | ESCC | 2.16e-15 | 3.05e-01 | 0.1327 |
| 318 | NUDT2 | P8T-E | Human | Esophagus | ESCC | 3.84e-15 | 1.32e-01 | 0.0889 |
| 318 | NUDT2 | P9T-E | Human | Esophagus | ESCC | 1.41e-19 | 3.75e-01 | 0.1131 |
| 318 | NUDT2 | P10T-E | Human | Esophagus | ESCC | 8.45e-19 | 3.24e-01 | 0.116 |
| 318 | NUDT2 | P11T-E | Human | Esophagus | ESCC | 2.96e-06 | 3.85e-01 | 0.1426 |
| 318 | NUDT2 | P12T-E | Human | Esophagus | ESCC | 4.41e-23 | 4.01e-01 | 0.1122 |
| 318 | NUDT2 | P15T-E | Human | Esophagus | ESCC | 4.22e-12 | 9.11e-02 | 0.1149 |
| 318 | NUDT2 | P16T-E | Human | Esophagus | ESCC | 1.50e-17 | 3.05e-01 | 0.1153 |
| 318 | NUDT2 | P17T-E | Human | Esophagus | ESCC | 7.37e-11 | 2.92e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000911719 | Oral cavity | OSCC | nucleotide metabolic process | 243/7305 | 489/18723 | 7.80e-07 | 1.09e-05 | 243 |
| GO:00091233 | Oral cavity | OSCC | nucleoside monophosphate metabolic process | 50/7305 | 76/18723 | 2.04e-06 | 2.62e-05 | 50 |
| GO:001969319 | Oral cavity | OSCC | ribose phosphate metabolic process | 199/7305 | 396/18723 | 2.97e-06 | 3.64e-05 | 199 |
| GO:00506854 | Oral cavity | OSCC | positive regulation of mRNA processing | 25/7305 | 32/18723 | 7.52e-06 | 8.14e-05 | 25 |
| GO:000925919 | Oral cavity | OSCC | ribonucleotide metabolic process | 189/7305 | 385/18723 | 3.18e-05 | 2.87e-04 | 189 |
| GO:00091614 | Oral cavity | OSCC | ribonucleoside monophosphate metabolic process | 38/7305 | 58/18723 | 3.91e-05 | 3.43e-04 | 38 |
| GO:00063792 | Oral cavity | OSCC | mRNA cleavage | 18/7305 | 22/18723 | 5.05e-05 | 4.23e-04 | 18 |
| GO:00091242 | Oral cavity | OSCC | nucleoside monophosphate biosynthetic process | 29/7305 | 42/18723 | 7.73e-05 | 6.00e-04 | 29 |
| GO:00091268 | Oral cavity | OSCC | purine nucleoside monophosphate metabolic process | 30/7305 | 44/18723 | 8.41e-05 | 6.44e-04 | 30 |
| GO:0051259 | Oral cavity | OSCC | protein complex oligomerization | 121/7305 | 238/18723 | 1.29e-04 | 9.21e-04 | 121 |
| GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
| GO:000915020 | Oral cavity | OSCC | purine ribonucleotide metabolic process | 178/7305 | 368/18723 | 1.45e-04 | 1.02e-03 | 178 |
| GO:000616320 | Oral cavity | OSCC | purine nucleotide metabolic process | 188/7305 | 396/18723 | 3.31e-04 | 2.04e-03 | 188 |
| GO:00091562 | Oral cavity | OSCC | ribonucleoside monophosphate biosynthetic process | 23/7305 | 33/18723 | 3.47e-04 | 2.12e-03 | 23 |
| GO:00091677 | Oral cavity | OSCC | purine ribonucleoside monophosphate metabolic process | 27/7305 | 41/18723 | 4.54e-04 | 2.74e-03 | 27 |
| GO:00987871 | Oral cavity | OSCC | mRNA cleavage involved in mRNA processing | 12/7305 | 14/18723 | 4.62e-04 | 2.76e-03 | 12 |
| GO:19012938 | Oral cavity | OSCC | nucleoside phosphate biosynthetic process | 125/7305 | 256/18723 | 8.32e-04 | 4.41e-03 | 125 |
| GO:00091658 | Oral cavity | OSCC | nucleotide biosynthetic process | 124/7305 | 254/18723 | 8.79e-04 | 4.63e-03 | 124 |
| GO:00987892 | Oral cavity | OSCC | pre-mRNA cleavage required for polyadenylation | 11/7305 | 13/18723 | 1.02e-03 | 5.29e-03 | 11 |
| GO:004639017 | Oral cavity | OSCC | ribose phosphate biosynthetic process | 95/7305 | 190/18723 | 1.30e-03 | 6.46e-03 | 95 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
| hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
| hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
| hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
| hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
| hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
| hsa0024021 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
| hsa0024031 | Oral cavity | LP | Pyrimidine metabolism | 28/2418 | 58/8465 | 1.12e-03 | 5.02e-03 | 3.24e-03 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUDT2 | SNV | Missense_Mutation | novel | c.90N>T | p.Gln30His | p.Q30H | P50583 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| NUDT2 | SNV | Missense_Mutation | c.334N>G | p.Gln112Glu | p.Q112E | P50583 | protein_coding | deleterious(0.03) | possibly_damaging(0.468) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NUDT2 | SNV | Missense_Mutation | novel | c.439N>A | p.Ala147Thr | p.A147T | P50583 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NUDT2 | deletion | Frame_Shift_Del | novel | c.268delA | p.Thr90GlnfsTer9 | p.T90Qfs*9 | P50583 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| NUDT2 | SNV | Missense_Mutation | novel | c.439N>A | p.Ala147Thr | p.A147T | P50583 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| NUDT2 | SNV | Missense_Mutation | novel | c.151N>T | p.Asp51Tyr | p.D51Y | P50583 | protein_coding | deleterious(0.04) | possibly_damaging(0.482) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NUDT2 | SNV | Missense_Mutation | c.30C>G | p.Ile10Met | p.I10M | P50583 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-05-4389-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NUDT2 | SNV | Missense_Mutation | c.344G>A | p.Arg115His | p.R115H | P50583 | protein_coding | deleterious(0.01) | possibly_damaging(0.825) | TCGA-49-4501-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | gemzar | PD | |
| NUDT2 | SNV | Missense_Mutation | novel | c.431N>G | p.Ser144Cys | p.S144C | P50583 | protein_coding | deleterious(0) | possibly_damaging(0.645) | TCGA-90-A4EE-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
| NUDT2 | SNV | Missense_Mutation | c.30C>G | p.Ile10Met | p.I10M | P50583 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-CX-7086-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |